Abstract
The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease. Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Letter
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antimetabolites, Antineoplastic / administration & dosage
-
Antimetabolites, Antineoplastic / pharmacology*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Immunotherapy* / adverse effects
-
Infection Control
-
Infections / etiology
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
-
Male
-
Methylprednisolone / adverse effects
-
Methylprednisolone / pharmacology
-
Methylprednisolone / therapeutic use*
-
Middle Aged
-
Rituximab
-
Salvage Therapy*
-
Vidarabine / administration & dosage
-
Vidarabine / analogs & derivatives*
-
Vidarabine / pharmacology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Rituximab
-
Vidarabine
-
fludarabine
-
Methylprednisolone